29 September 2015

Positive headline data from RPL554 study

VERONA PHARMA PLC - Positive headline data from RPL554 study

Read more

29 September 2015

Positive headline data from RPL554 clinical study in COPD patients

Read more

8 September 2015

Board Changes

VERONA PHARMA PLC - Board Changes

Read more

8 September 2015

Half-yearly Report

VERONA PHARMA PLC - Half-yearly Report

Read more

27 August 2015

Notice of Results

VERONA PHARMA PLC - Notice of Results

Read more

7 July 2015

Director Dealing

VERONA PHARMA PLC - Director Dealing

Read more

17 June 2015

Director Dealings

VERONA PHARMA PLC - Director Dealings

Read more

12 June 2015

Secondary listing in Germany

VERONA PHARMA PLC - Secondary listing in Germany

Read more

11 June 2015

RPL554 Phase 2a trial started

VERONA PHARMA PLC - RPL554 Phase 2a trial started

Read more

11 June 2015

Result of AGM

VERONA PHARMA PLC - Result of AGM

Read more

Targeting unmet needs

384m people worldwide suffer from COPD and 37 years is the median life expectancy of CF patients

Read more about COPD and CF in the unmet needs section of this website

Go

The Lancet Respiratory Medicine

Peer-reviewed paper in the Lancet's highly-respected medication journal

Basic & Clinical Pharmacology & Toxicology

Peer-reviewed publication on dual PDE3/4 inhibitors as novel treatments for COPD

Close

Verona Pharma plc
3 More London Riverside, London SE1 2RE
T: +44 (0)203 283 4200

Linkedin     Email Us